Abstract 179P
Background
The elderly have numerous risk factors, such as comorbidities, undernutrition, and sarcopenia. Therefore, they require careful treatment indications and management in cancer treatment. Body composition and sarcopenia assessment have been performed in gastric cancer preoperative patients to improve perioperative outcomes since 2018, and we have provided nutritional/rehabilitative assessments and medical support to eligible patients with collaborative practice (CP).
Methods
Of 881 patients with gastrectomy between January 2011 and April 2023, aged 80 years or older were included in this study. We compared the short-term perioperative outcomes of patients with preoperative nutritional/rehabilitative assessments and support with CP (supportive (S) group) and without this assessment (non-supportive (NS) group).
Results
Sixty patients in the S group and 103 in the NS group. There were no differences in age, gender, performance status, Charlson comorbidity index, clinical Stage, or preoperative nutritional assessment, but the S group had a higher body mass index (median; S: 22.2 mg/m2 vs. NS: 21.5 mg/m2, p=0.02) and higher ASA-PS (ASA-PS ≥3, S: 48.4 vs. NS: 24.8%, p=0.002). The S group had fewer total gastrectomies (S: 15.0% vs. NS: 29.1%, p=0.037) and more robotic/laparoscopic approaches (S: 75.0% vs. NS: 30.1%, p<0.001). There was no difference in operative time but less blood loss in the S group (S: 50ml vs. NS: 230ml, p<0.001). Overall complications were lower in the S group (S: 20.0% vs. NS: 36.9%, p=0.021), but there was no difference in Clavien-Dindo ≥3 or higher complications (S: 6.7% vs. NS: 12.6%, p=0.21). In particular, the S group had fewer surgical site infections (S: 6.7% vs. NS: 17.5%, p=0.041) and pneumonia (S: 3.3% vs. NS: 15.5%, p=0.009). Postoperative hospital stay was shorter in the S group (S: 11 days vs. NS: 16 days, p<0.001).
Conclusions
Our results suggest that pre-operative nutritional/rehabilitative assessments and support in elderly gastric cancer patients led to fewer postoperative infectious complications and shorter hospital stays.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sakai City Medical Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract